Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs
Antibody drug conjugates deliver a targeted strike to tumors, but the toxic payloads of these therapies can still reach healthy tissue. Mythic Therapeutics' FateControl technology ensures that more of an ADC's drug payload reaches the tumor, and CEO Alex Nichols is steering the startup out of stealth with $103 million and a lead program in lung cancer.